Biosimilars Global Market Report 2025

Description

Biosimilars are medications made from living things, though they can be made in a variety of ways and with slightly different materials. Due to the intricacy and high cost of their creation, as well as their molecular size and structure, biosimilars are fundamentally distinct from generic drugs.

The main types of biosimilars are human growth hormone, erythropoietin, monoclonal antibodies, insulin, interferon, granulocyte-colony stimulating factor, and others. Erythropoietin is a hormone produced by the kidneys to stimulate the production and maintenance of vital red blood cells. The various products include recombinant non-glycosylated proteins and recombinant glycosylated proteins that are used for the treatment of oncology, chronic and autoimmune diseases, growth hormone deficiency, infectious diseases, and others.

The biosimilars market research report is one of a series of new reports from The Business Research Company that provides biosimilars market statistics, including biosimilars industry global market size, regional shares, competitors with a biosimilars market share, detailed biosimilars market segments, market trends, and opportunities, and any further data you may need to thrive in the biosimilars industry. This biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The biosimilars market size has grown rapidly in recent years. It will grow from $18.65 billion in 2024 to $21.95 billion in 2025 at a compound annual growth rate (CAGR) of 17.7%. The growth in the historic period can be attributed to an increase in cancer prevalence, strong economic growth in emerging markets, an increase in pharmaceutical R&D expenditure, increased healthcare expenditure, growing government initiatives, a strong pipeline of drugs, low cost of biosimilars and an increase in patent expiration.

The biosimilars market size is expected to see rapid growth in the next few years. It will grow to $42.16 billion in 2029 at a compound annual growth rate (CAGR) of 17.7%. The growth in the forecast period can be attributed to the increasing prevalence of cancer, increasing demand for prophylaxis with granulocyte colony-stimulating factor (G-CSF), a rise in healthcare expenditure, high potential of emerging economies, technology advances, high penetration of biological drugs, aging population and an increase in healthcare access will drive the growth. Major trends in the forecast period include a focus on robust R&D activities for the development of effective and innovative drugs, on focus on M&A growth strategies, a focus on establishing strategic partnerships, a focus on increasing investments, and a focus on artificial intelligence.

The biosimilars market is anticipated to witness significant growth due to the escalating prevalence of chronic diseases such as arthritis, asthma, and cancer. Factors such as prolonged work hours, limited physical activity, and unhealthy lifestyle choices contribute to the increased occurrence of these conditions, for which biosimilars are increasingly becoming a preferred treatment option. Biosimilars play a crucial role in stimulating the immune system response against cancer cells, aiding in their elimination from the body. As per a United Nations projection, by 2030, chronic diseases are estimated to account for around 70% of global deaths, with the global burden of chronic disease expected to reach approximately 60%. Consequently, this upsurge in chronic disease prevalence is set to drive the demand for biosimilars, consequently propelling the biosimilars market.

The rise in healthcare expenditures is anticipated to drive the growth of the biosimilars market in the future. Healthcare expenditures refer to the overall spending on healthcare goods and services within a specific population or healthcare system. The biosimilars market contributes to reducing healthcare expenditures by providing more affordable alternatives to costly biologic drugs, which helps lower treatment costs for patients and healthcare systems. For example, in March 2024, the Health Foundation, a UK-based independent charity and think tank, reported that total health expenditures in England reached £182 billion ($196.78 billion) in the last confirmed year of spending data, 2022/23. Although planned health spending is projected to increase to £192 billion ($207.59 billion) in 2024/25, inflation is expected to result in only a modest real-term increase of 0.6% compared to the fiscal year 2023/24. Thus, the growing healthcare expenditures are fueling the expansion of the biosimilars market.

Key players in the biosimilars market are heavily invested in pioneering innovative products to establish a competitive edge. Notably, AMJEVITA marks a significant milestone as the inaugural U.S. biosimilar to Humira, a medication relied upon by over a million patients managing severe inflammatory conditions. In January 2023, Amgen Inc., a prominent biotechnology company, introduced AMJEVITA (adalimumab-atto) into the U.S. market. This biosimilar, available at 55% and 5% below the list price of Humira, offers patients a more cost-effective option.

Major companies within the biosimilars domain persist in crafting novel solutions. FYLNETRA represents a leap forward as a leukocyte growth factor designed to lower infection incidence, particularly febrile neutropenia, in patients with non-myeloid malignancies undergoing myelosuppressive anti-cancer treatments. In May 2023, Amneal Pharmaceuticals Inc., a distinguished pharmaceutical entity, launched the commercial debut of FYLNETRA (pegfilgrastim-pbbk), a Neulasta-referenced biosimilar delivered in a pre-filled single-dose syringe. FYLNETRA aims to address neutropenia, commonly experienced by chemotherapy patients, presenting a significant advancement in biosimilar-based treatments.

In November 2022, Biocon Biologics Ltd., an Indian biopharmaceutical company, announced the acquisition of Viatris Inc.'s biosimilars business for $3 billion. This strategic move aims to enhance Biocon Biologics' proximity to patients, customers, and payors by providing direct commercial capabilities and supporting infrastructure in advanced countries and various emerging regions. The merger combines Viatris' acquired global biosimilars business with Biocon Biologics' existing capabilities in research and development, global-scale manufacturing, and commercialization. Viatris Inc. is a US-based pharmaceutical company specializing in the development, licensing, manufacturing, marketing, and distribution of generic and branded medicines.

Major companies operating in the biosimilars market include Amgen, Novartis AG, Samsung Bioepis Co., Ltd., Viatris, Celltrion, Inc., Coherus Biosciences, Eli Lilly and Company, Dr. Reddy's Laboratories, Roche India Pvt Ltd, Abbott India Limited, bioMerieux India, Becton Dickinson Private Limited, Danaher Corporation, Wuxi biologics, shanghai Henlius biotech, Innovent Biologics, Hisun Pharma, 3SBio, Beijing ShuangLu Pharmaceuticals, Qilu Pharmaceutical, Kyowa Hakko Kirin, Takeda, Mitsubishi Tanabe, AGC Biologics, Bio-Thera, Sandoz Pty Ltd, Apotex Pty Ltd, Cadila Pharmaceuticals, BiosanaPharma, GlaxoSmithKline, AstraZeneca, Bayer, Merck, Boehringer Ingelheim, Sanofi, Fresenius Kabi, Napp Pharmaceuticals, Mundipharma Deutschland GmbH & Co. KG, Geropharm, Valenta, NovaMedica, SynBio, Rani Therapeutics, Johnson & Johnson, Biogen Inc., Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Cipla Medpro South Africa, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty)

North America was the largest region in the global biosimilars market in 2024. Middle East is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The biosimilars market consists of sales of binocrit, epoetin alfa hexal, and abseamed. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Biosimilars Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Monoclonal Antibodies, Insulin, Erythropoietin, Granulocyte-Colony Stimulating Factor, Other Hormones, Others
2) By Product: Recombinant Non-glycosylated Proteins, Recombinant Glycosylated Proteins
3) By Application: Oncology, Chronic And Autoimmune Diseases, Growth Hormone Deficiency, Infectious Diseases, Other Applications
Subsegments:
1) By Monoclonal Antibodies: IgG Biosimilars; Non-IgG Biosimilars
2) By Insulin: Rapid-Acting Insulin Biosimilars; Long-Acting Insulin Biosimilars; Premixed Insulin Biosimilars
3) By Erythropoietin: Epoetin Alfa Biosimilars; Darbepoetin Alfa Biosimilars
4) By Granulocyte-Colony Stimulating Factor (G-CSF): Filgrastim Biosimilars; Pegfilgrastim Biosimilars
5) By Other Hormones: Growth Hormones; Hormonal Replacement Therapy Biosimilars
6) By Others: Enzyme Biosimilars; Vaccines; Other Biologics
Companies Mentioned: Amgen; Novartis AG; Samsung Bioepis Co., Ltd.; Viatris; Celltrion, Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r25499

1. Executive Summary

2. Biosimilars Market Characteristics

3. Biosimilars Market Trends And Strategies

4. Biosimilars Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Biosimilars Growth Analysis And Strategic Analysis Framework

5.1. Global Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Biosimilars Market Growth Rate Analysis
5.4. Global Biosimilars Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Biosimilars Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Biosimilars Total Addressable Market (TAM)

6. Biosimilars Market Segmentation

6.1. Global Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
Insulin
Erythropoietin
Granulocyte-Colony Stimulating Factor
Other Hormones
Others
6.2. Global Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Recombinant Non-glycosylated Proteins
Recombinant Glycosylated Proteins
6.3. Global Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oncology
Chronic And Autoimmune Diseases
Growth Hormone Deficiency
Infectious Diseases
Other Applications
6.4. Global Biosimilars Market, Sub-Segmentation Of Monoclonal Antibodies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
IgG Biosimilars
Non-IgG Biosimilars
6.5. Global Biosimilars Market, Sub-Segmentation Of Insulin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Rapid-Acting Insulin Biosimilars
Long-Acting Insulin Biosimilars
Premixed Insulin Biosimilars
6.6. Global Biosimilars Market, Sub-Segmentation Of Erythropoietin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Epoetin Alfa Biosimilars
Darbepoetin Alfa Biosimilars
6.7. Global Biosimilars Market, Sub-Segmentation Of Granulocyte-Colony Stimulating Factor (G-CSF), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Filgrastim Biosimilars
Pegfilgrastim Biosimilars
6.8. Global Biosimilars Market, Sub-Segmentation Of Other Hormones, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Growth Hormones
Hormonal Replacement Therapy Biosimilars
6.9. Global Biosimilars Market, Sub-Segmentation Of Others, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Enzyme Biosimilars
Vaccines
Other Biologics

7. Biosimilars Market Regional And Country Analysis

7.1. Global Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Biosimilars Market

8.1. Asia-Pacific Biosimilars Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Biosimilars Market

9.1. China Biosimilars Market Overview
9.2. China Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Biosimilars Market

10.1. India Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Biosimilars Market

11.1. Japan Biosimilars Market Overview
11.2. Japan Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Biosimilars Market

12.1. Australia Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Biosimilars Market

13.1. Indonesia Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Biosimilars Market

14.1. South Korea Biosimilars Market Overview
14.2. South Korea Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Biosimilars Market

15.1. Western Europe Biosimilars Market Overview
15.2. Western Europe Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Biosimilars Market

16.1. UK Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Biosimilars Market

17.1. Germany Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Biosimilars Market

18.1. France Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Biosimilars Market

19.1. Italy Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Biosimilars Market

20.1. Spain Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Biosimilars Market

21.1. Eastern Europe Biosimilars Market Overview
21.2. Eastern Europe Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Biosimilars Market

22.1. Russia Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Biosimilars Market

23.1. North America Biosimilars Market Overview
23.2. North America Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Biosimilars Market

24.1. USA Biosimilars Market Overview
24.2. USA Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Biosimilars Market

25.1. Canada Biosimilars Market Overview
25.2. Canada Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Biosimilars Market

26.1. South America Biosimilars Market Overview
26.2. South America Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Biosimilars Market

27.1. Brazil Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Biosimilars Market

28.1. Middle East Biosimilars Market Overview
28.2. Middle East Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Biosimilars Market

29.1. Africa Biosimilars Market Overview
29.2. Africa Biosimilars Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Biosimilars Market Competitive Landscape And Company Profiles

30.1. Biosimilars Market Competitive Landscape
30.2. Biosimilars Market Company Profiles
- 30.2.1. Amgen Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Samsung Bioepis Co., Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Viatris Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Celltrion, Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Biosimilars Market Other Major And Innovative Companies

31.1. Coherus Biosciences
31.2. Eli Lilly and Company
31.3. Dr. Reddy's Laboratories
31.4. Roche India Pvt Ltd
31.5. Abbott India Limited
31.6. bioMerieux India
31.7. Becton Dickinson Private Limited
31.8. Danaher Corporation
31.9. Wuxi biologics
31.10. shanghai Henlius biotech
31.11. Innovent Biologics
31.12. Hisun Pharma
31.13. 3SBio
31.14. Beijing ShuangLu Pharmaceuticals
31.15. Qilu Pharmaceutical

32. Global Biosimilars Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Biosimilars Market

34. Recent Developments In The Biosimilars Market

35. Biosimilars Market High Potential Countries, Segments and Strategies

35.1 Biosimilars Market In 2029 - Countries Offering Most New Opportunities
35.2 Biosimilars Market In 2029 - Segments Offering Most New Opportunities
35.3 Biosimilars Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer